The FDA has received 8,530 adverse event reports for cats that name Sarolaner.
- 8,530 reports name Sarolaner in cats, which is 5.6% of all 151,164 cat reports. A report counts under every active ingredient it names.
- 34% are marked serious and 2.6% record a death or euthanasia; across all cat reports those figures are 27% and 9.4%.
- 19% are complaints that the product did not work (19% across all cat reports).
- The clinical signs reported most are application site hair loss, application site alopecia and application site scab.
- The FDA lists 1 approved animal drug application containing Sarolaner for cats, the earliest approved in 2018.
- None of this is a rate. The FDA data does not record how many cats were given Sarolaner, so it cannot say how often any of this happens.
How the reports break down
| What the reports say | Reports | Share of this medicine's reports | All cat reports |
|---|---|---|---|
| Marked seriousthe FDA record flags the report as serious | 2,915 | 34% | 27% |
| Death or euthanasiathe outcome recorded in the report, with no finding of cause | 222 | 2.6% | 9.4% |
| Did not worka complaint that the product failed to work, which the FDA files as an adverse event | 1,648 | 19% | 19% |
| Seizurea seizure or convulsion is among the clinical signs | 377 | 4.4% | 2.6% |
| Not used per labelthe report says the product was not used the way its label directs | 1,423 | 17% | 33% |
Where on the body do the reported signs sit?
Not on the body: Whole body 11% Did not work 8.7%
- Where it was applied49%application site hair loss, application site alopecia, application site scab, application site reddening and 4 more
- Stomach and gut18%vomiting, anorexia, not eating, diarrhoea and 2 more
- Whole body11%lethargy, lethargy, fever
- Did not work8.7%lack of efficacy (ectoparasite) - flea, lack of efficacy (endoparasite) - tapeworm
- Brain and nerves8.5%seizure, ataxia, tremor, twitching
- Behaviour4.5%behavioural disorder, hiding
Each figure is a share of sign mentions among the 25 signs reported most for Sarolaner in cats. One report can list several signs, so these do not add up to reports. The grouping into body systems is ours; the signs in each group are listed beside it.
Clinical signs reported most
- Application site hair loss2,396 28%
- Application site alopecia733 8.6%
- Application site scab710 8.3%
- Lack of efficacy (ectoparasite) - flea705 8.3%
- Vomiting697 8.2%
- Lethargy678 8.0%
- Application site reddening506 5.9%
- Lethargy361 4.2%
Reports received per year
Is it approved for cats?
The FDA lists 1 approved animal drug application containing Sarolaner for cats, the earliest approved in 2018.
| Product | Form | Approved for | First approved | FDA application |
|---|---|---|---|---|
| Revolution PlusZoetis Inc. | Topical Solution RX | Cat | 2018 | 141-502 |
What can you do next?
Report counts: FDA Center for Veterinary Medicine adverse event reports, read 11 November 2026 (FDA data last updated 5 October 2026). Approvals: Animal Drugs @ FDA, read 11 November 2026. Counts are reports, not animals and not doses.
Where can you go from this result?
This result is one of 94 in the lookup. See Sarolaner in dogs (70,962 reports). Open it in the lookup to set it beside another medicine, or read how the counts were collected.
- Cefovecin in cats8,686
- Nitenpyram in cats8,753
- Frunevetmab in cats8,036
- Imidacloprid in cats9,231
To report a suspected side effect in your own animal, follow how to report an animal drug side effect to the FDA. The FDA explains what a report can and cannot show in openFDA's guide to reading the results.
Compiled by Vincent Wesley Couey, PetMaxxing Research (ORCID 0009-0005-6869-308X). Sources: openFDA animal and veterinary adverse event interface; Animal Drugs @ FDA.